Clinical trial
Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal…
NCT00295594 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00295594 |
|---|---|
| Title | Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation. |
| Official title | An Open, Randomised, Multicenter, Clinical Study to Compare the Safety and Efficacy of Tacrolimus and Minimal Steroids in Combination With Either a Monoclonal Anti-IL2R Antibody (Daclizumab) or Mycophenolate Mofetil in Liver Allograft Transplantation. |
| Acronym | MARSILEA |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Liver Transplantation |
| Intervention type | Drug |
| Interventions | tacrolimus |
| Enrollment | 627 |
| Start date | Mar 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Feb 24, 2006 |
| Last update posted | Aug 26, 2014 |
| Countries | Belgium, Denmark, Finland, Germany, Hungary, Italy, Poland, Spain, Sweden, Switzerland, United Kingdom |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: